Clinical Trial Update: A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of VVN432 nasal spray in chronic rhinosinusitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis

Drugs mentioned

• VVN432 nasal spray (VVN432)

Snippet

Sponsor: VivaVision Biotech, Inc | Conditions: Chronic Rhinosinusitis (CRS) | Phase 1 | Status: RECRUITING